MAPT and Alzheimer disease: In clinical settings, cerebrospinal fluid (CSF) sTREM2 functions as a dynamic biomarker indicating microglial activation intensity, with elevated levels in AD patients correlating strongly with neurodegeneration markers (T-tau and P-tau181) [11].